Phase I study of the specific endothelin A receptor antagonist zibotentan (ZD4054) combined with docetaxel in patients with metastatic castration-resistant prostate cancer: Assessment of efficacy, pain, and safety.
Year: 2010
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: D. L. Trump, H. Payne, K. Miller, J. S. De Bono, J. Stephenson, H. A. Burris, F. E. Nathan, M. Taboada, T. Morris, A. Hübner
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2278085608